@prefix pubblicazioni: . @prefix unitaDiPersonaleInterno: . @prefix prodotto: . unitaDiPersonaleInterno:MATRICOLA5636 pubblicazioni:autoreCNRDi prodotto:ID271429 . @prefix prodottidellaricerca: . @prefix istituto: . istituto:CDS009 prodottidellaricerca:prodotto prodotto:ID271429 . @prefix modulo: . modulo:ID2644 prodottidellaricerca:prodotto prodotto:ID271429 . @prefix rdf: . @prefix retescientifica: . prodotto:ID271429 rdf:type retescientifica:ProdottoDellaRicerca , prodotto:TIPO1101 . @prefix rdfs: . prodotto:ID271429 rdfs:label "Direct inhibition of hexokinase activity by metformin at least partially impairs glucose metabolism and tumor growth in experimental breast cancer. (Articolo in rivista)"@en . @prefix xsd: . prodotto:ID271429 pubblicazioni:anno "2013-01-01T00:00:00+01:00"^^xsd:gYear ; pubblicazioni:doi "10.4161/cc.26461"^^xsd:string . @prefix skos: . prodotto:ID271429 skos:altLabel "
Cecilia Marini 1, Barbara Salani 2, Michela Massollo 3, Adriana Amaro 4, Alessia Isabella Esposito 4, Anna Maria Orengo 3, Selene Capitanio 3, Laura Emionite 5, Mattia Riondato 3, Gianluca Bottoni 3, Cinzia Massara 3, Simona Boccardo 6, Marina Fabbi 7, Cristina Campi 8, Silvia Ravera 9, Giovanna Angelini 4, Silvia Morbelli 3, Michele Cilli 5, Renzo Cordera 2, Mauro Truini 6, Davide Maggi 2, Ulrich Pfeffer 4, Gianmario Sambuceti 3 (2013)
Direct inhibition of hexokinase activity by metformin at least partially impairs glucose metabolism and tumor growth in experimental breast cancer.
in Cell cycle (Georgetown, Tex. Online)
"^^rdf:HTML ; pubblicazioni:autori "Cecilia Marini 1, Barbara Salani 2, Michela Massollo 3, Adriana Amaro 4, Alessia Isabella Esposito 4, Anna Maria Orengo 3, Selene Capitanio 3, Laura Emionite 5, Mattia Riondato 3, Gianluca Bottoni 3, Cinzia Massara 3, Simona Boccardo 6, Marina Fabbi 7, Cristina Campi 8, Silvia Ravera 9, Giovanna Angelini 4, Silvia Morbelli 3, Michele Cilli 5, Renzo Cordera 2, Mauro Truini 6, Davide Maggi 2, Ulrich Pfeffer 4, Gianmario Sambuceti 3"^^xsd:string ; pubblicazioni:paginaInizio "3490"^^xsd:string ; pubblicazioni:paginaFine "3499"^^xsd:string ; pubblicazioni:altreInformazioni "IF 2012: 5.321"^^xsd:string ; pubblicazioni:numeroVolume "12"^^xsd:string . @prefix ns11: . prodotto:ID271429 pubblicazioni:rivista ns11:ID67677 ; pubblicazioni:numeroFascicolo "22"^^xsd:string ; skos:note "PubMe"^^xsd:string ; pubblicazioni:affiliazioni "1. CNR Institute of Bioimages and Molecular physiology, Milan, Section of Genoa, Genoa, Italy.\n2. Chair of Diabetology, Department of Internal Medicine, University of Genoa, IRCCS San Martino-National Institute of Cancer, Genoa, Italy.\n3. Nuclear Medicine, Department of Health Science, University of Genoa, IRCCS San Martino-National Institute of Cancer, Genoa, Italy.\n4. Department of Integrated Molecular Pathology, IRCCS San Martino-National Institute of Cancer, Genoa, Italy. \n5. Animal Facility, IRCCS San Martino-National Institute of Cancer, Genoa, Italy.\n6. Department of pathology, IRCCS San Martino-National Institute of Cancer, Genoa, Italy.\n7. Department of Integrated Oncological Therapies, IRCCS San Martino-National Institute of Cancer, Genoa, Italy.\n8. Department of Mathematics, University of Genoa, Genoa, Italy.\n9. Department of Pharmacy, University of Genoa, Genoa, Italy."^^xsd:string ; pubblicazioni:titolo "Direct inhibition of hexokinase activity by metformin at least partially impairs glucose metabolism and tumor growth in experimental breast cancer."^^xsd:string ; prodottidellaricerca:abstract "Emerging evidence suggests that metformin, a widely used anti-diabetic drug, may be useful in the prevention and treatment of different cancers. In the present study, we demonstrate that metformin directly inhibits the enzymatic function of hexokinase (HK) I and II in a cell line of triple-negative breast cancer (MDA-MB-231). The inhibition is selective for these isoforms, as documented by experiments with purified HK I and II as well as with cell lysates. Measurements of 18F-fluoro-deoxyglycose uptake document that it is dose- and time-dependent and powerful enough to virtually abolish glucose consumption despite unchanged availability of membrane glucose transporters. The profound energetic imbalance activates phosphorylation and is subsequently followed by cell death. More importantly, the \\\"in vivo\\\" relevance of this effect is confirmed by studies of orthotopic xenografts of MDA-MB-231 cells in athymic (nu/nu) mice. Administration of high drug doses after tumor development caused an evident tumor necrosis in a time as short as 48 h. On the other hand, 1 mo metformin treatment markedly reduced cancer glucose consumption and growth. Taken together, our results strongly suggest that HK inhibition contributes to metformin therapeutic and preventive potential in breast cancer."@en ; prodottidellaricerca:prodottoDi istituto:CDS009 , modulo:ID2644 ; pubblicazioni:autoreCNR unitaDiPersonaleInterno:MATRICOLA5636 . @prefix parolechiave: . prodotto:ID271429 parolechiave:insiemeDiParoleChiave . ns11:ID67677 pubblicazioni:rivistaDi prodotto:ID271429 . parolechiave:insiemeDiParoleChiaveDi prodotto:ID271429 .